MICREOS-PHARMACEUTICALS
5.4.2022 11:05:12 CEST | Business Wire | Press release
Micreos Pharmaceuticals today announces the expansion of its leadership team to include Trine Ahlgreen as Chief Business Officer and Carsten Edwards as Chief Development Officer. Their significant leadership experience within large, global pharmaceutical organisations will enable Micreos to accelerate the journey of developing viable alternatives to traditional antibiotics in select medical indications by leveraging proprietary endolysin technology, which selectively targets and kills harmful bacteria while preserving the rest of the microbiome.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005632/en/
The addition of Trine Ahlgreen and Carsten Edwards to the senior team represents an important step forward in building the strategic capabilities to make the right choices in the months and years ahead.
As Chief Business Officer, Trine Ahlgreen is responsible for building-out the pharmaceutical business strategy including commercial input into the development program and the selection & prioritisation of new indications where bacteria are the underlying pathogen. She will also be responsible for forging partnerships with pharma and diagnostic companies to design the go-to-market strategies and deliver solutions to improve patient standards-of-care. Trine has spent the last 20 years at Novo Nordisk in various geographies leading marketing and sales operations across the company’s portfolio.
Carsten Edwards brings 30 years of diverse experience in value, access, pricing, and health economics outcomes functions across companies including Novo Nordisk, AbbVie, and Bristol-Myers Squibb. Carsten has also worked in consultancy and is a recognised expert in drug development and the data packages required to secure global patient access. As Chief Development Officer, Carsten will lead Micreos Pharmaceuticals’ entire drug development programs, including pre-clinical, analytical methods development, API manufacturing, and drug formulation development, to optimise therapeutic effect and to maximise patient outcomes
“We are delighted to expand our senior team at this critical moment in the Micreos
Pharmaceuticals’ journey and to attract people of the calibre of Carsten and Trine into our organisation. They are among the very best people in our industry,” said Matt Regan, CEO of Micreos Pharmaceuticals, who joined the company in October 2021. “Trine and Carsten bring significant pharmaceutical industry experience, success, and know-how that will help us to make the right choices in early drug discovery and in our pharmaceutical development programs to ensure that we are raising the standards of care for patients in our selected disease areas.”
About Micreos Pharmaceuticals
Micreos Pharmaceuticals develops new biological therapies based on the targeted killing of unwanted bacteria, which has medical potential in a broad range of applications. The company is viewed as a global leader in this field. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH in Zurich.
Micreos Pharmaceuticals is located in Zug, Switzerland and has a Drug discovery / Technology research centre in Zurich, Switzerland with a Drug development & Clinical operation in Bilthoven in the Netherlands.
About Antimicrobial Resistance (AMR)
AMR is an issue of growing global importance which results in 750,000 deaths per year . It occurs when pathogens adapt so that the drugs used to treat infections become less effective. If not addressed, the spread of antibiotic-resistant pathogens could continue to rise, leading to highly dangerous superbugs. The number of annual global deaths from AMR is projected to increase to 10 million by 2050 — which is more people than die globally of cancer today – unless successful alternatives to antibiotics are developed.
Micreos Pharmaceuticals intends to play a very significant role in addressing AMR and the great unmet medical need for a safe alternative to antibiotics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005632/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Announces Dates for First-Quarter 2026 Results Conference Call26.3.2026 18:00:00 CET | Press release
SLB (NYSE:SLB) will hold a conference call on April 24, 2026, to discuss the results for the first quarter ending March 31, 2026. The conference call is scheduled to begin at 11:00 a.m. US Eastern time and a press release regarding the results will be issued at 7:00 a.m. US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 742955. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/972985185 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until May 1, 2026, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929)
Andersen Consulting indgår samarbejde med Stratis Consulting i Irland26.3.2026 16:56:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Stratis Consulting, der er et Dublin-baseret firma med speciale i strategiske ansættelsesforhold, personalepolitik og arbejdspladspolitikker. Stratis Consulting blev grundlagt i 2017 og er et rådgivningsfirma, der er anerkendt for sin dybe ekspertise inden for ansættelsesforhold og ledelsesstrategi. Firmaet arbejder tæt sammen med topledere, bestyrelser og hr-ledere som betroet rådgiver for at udvikle praktiske, menneskecentrerede løsninger, der øger engagement, styrker ledelseseffektivitet og tilpasser arbejdsstyrkens strategi med langsigtede forretningsmål. Stratis Consulting støtter organisationer i forbindelse med fusioner og opkøb samt større forandringsprocesser for at sikre effektiv implementering af arbejdsstyrkestrategier. "Hos Stratis mener vi, at personalestrategi i kombination med succesfulde ansættelsesforhold er forretningsstrategi," udtalte Brendan McGinty, administrerende partner hos Stratis Consulting. "Vores mål er at
CSG Named a Leader in the Gartner® Magic Quadrant™ for Customer Journey Analytics & Orchestration26.3.2026 16:30:00 CET | Press release
Rising customer expectations for connected, relevant, and effortless interactions are making journey analytics and orchestration critical to delivering consistent, personalized experiences that earn loyalty. As CSG® (NASDAQ: CSGS) helps businesses to meet and exceed those expectations, the company today announced that CSG has been named a Leader in the 2026 Gartner® Magic Quadrant™ for Customer Journey Analytics & Orchestration. The evaluation assessed the company’s overall Completeness of Vision and Ability to Execute. “It’s not enough to understand the customer – businesses must act on that knowledge in real time and prove the value of every customer interaction,” said Katie Costanzo, President, Customer Experience, CSG. “That requires a unified system that turns real-time data into clear decisions, measurable outcomes, and experiences customers can trust. I am incredibly proud that CSG has been named a Leader in the inaugural Gartner Magic Quadrant for Journey Analytics & Orchestrat
India: The Up-and-Coming Solar Market26.3.2026 16:27:00 CET | Press release
Solar energy expansion is booming worldwide. India, in particular, is seeing rapid growth thanks to state funding programs, tax incentives, subsidies and green loans from banks. In 2025, 37.5 gigawatts were added – a 50 percent increase from the previous year. The 2026 budget provides for a deployment of 45 to 50 gigawatts, allowing the most densely populated country to become the second largest solar market in the world. Intersolar Europe will shine a spotlight on the south Asian country from June 23–25 in Munich. India is an up-and-coming market for the international PV industry. There will be numerous events where visitors can learn about the market, new business opportunities and the structure of new supply chains. The exhibition will take place as part of The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry. More than 100,000 visitors and 2,800 exhibitors from all over the world are expected to attend. This press release features multimedia. View
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 14:00:00 CET | Press release
The combination connects AI-driven financial and operational planning, analytics and execution across Microsoft Excel and Power BI, removing decision latency for Microsoft-centric enterprises. Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap wid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom